Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib Plus Tislelizumab With or Without Nab-paclitaxel in TNBC
NCT04734262Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Apr 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitravatinib in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Apr 2021; status: active, not recruiting.
02
Drugs
sitravatinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04734262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734262.